Cargando…
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485082/ https://www.ncbi.nlm.nih.gov/pubmed/35821169 http://dx.doi.org/10.1007/s10067-022-06271-3 |
| _version_ | 1784792013078528000 |
|---|---|
| author | Coates, Laura C. Mease, Philip Kronbergs, Andris Helt, Cameron Sandoval, David Park, So Young Combe, Bernard Nash, Peter Deodhar, Atul |
| author_facet | Coates, Laura C. Mease, Philip Kronbergs, Andris Helt, Cameron Sandoval, David Park, So Young Combe, Bernard Nash, Peter Deodhar, Atul |
| author_sort | Coates, Laura C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9485082 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94850822022-09-21 Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results Coates, Laura C. Mease, Philip Kronbergs, Andris Helt, Cameron Sandoval, David Park, So Young Combe, Bernard Nash, Peter Deodhar, Atul Clin Rheumatol Correction Springer International Publishing 2022-07-11 2022 /pmc/articles/PMC9485082/ /pubmed/35821169 http://dx.doi.org/10.1007/s10067-022-06271-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Coates, Laura C. Mease, Philip Kronbergs, Andris Helt, Cameron Sandoval, David Park, So Young Combe, Bernard Nash, Peter Deodhar, Atul Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
| title | Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
| title_full | Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
| title_fullStr | Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
| title_full_unstemmed | Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
| title_short | Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results |
| title_sort | correction to: efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: spirit-p1 and spirit-p2 3-year results |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485082/ https://www.ncbi.nlm.nih.gov/pubmed/35821169 http://dx.doi.org/10.1007/s10067-022-06271-3 |
| work_keys_str_mv | AT coateslaurac correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT measephilip correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT kronbergsandris correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT heltcameron correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT sandovaldavid correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT parksoyoung correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT combebernard correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT nashpeter correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults AT deodharatul correctiontoefficacyandsafetyofixekizumabinpatientswithactivepsoriaticarthritiswithandwithoutconcomitantconventionaldiseasemodifyingantirheumaticdrugsspiritp1andspiritp23yearresults |